|Bid||4.2500 x 3000|
|Ask||4.4000 x 1000|
|Day's Range||3.9900 - 4.5700|
|52 Week Range||2.7600 - 10.7300|
|Beta (3Y Monthly)||1.43|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 13, 2017 - Nov 17, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.80|
CLEVELAND , Aug. 15, 2019 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will participate in two upcoming investor conferences in New York, NY . Event : Baird 2019 ...
President & CEO of Viewray Inc (30-Year Financial, Insider Trades) Scott William Drake (insider trades) bought 131,260 shares of VRAY on 08/13/2019 at an average price of $3.81 a share. Continue reading...
It seems that everyone wants to invest in tech these days. While the trade news from China has stoked fears about tech’s international exposure, the tech-heavy NASDAQ is still up 20% year-to-date. Tech is the go-to sector, getting headlines and analyst attention, and sometimes generating tremendous returns that justify the buzz.But not everyone has the budget to put down the four-figure share price for Alphabet or Amazon. Here we look at three tech stocks for value-conscious investors. These small-cap stocks present a low-cost option for entering the tech sector, and high upsides to make it worthwhile. NeoPhotonics Corporation (NPTN)Optoelectronics, using lasers, optical semiconductors, and photonic circuits to transmit and receive data streams in the high-volume 200+ gigabyte per second range, are the current leading edge in data transmission, and NeoPhotonics is a leader in the field. The company reported earnings last week, and beat the estimates by 70%. Analysts had expected the company to lose 10 cents per share, but the loss came in at 3 cents even though the quarterly revenues of $81.69 million just missed the forecast.NPTN was hit hard by the US-China trade tensions, especially as it is a major supplier for Chinese smartphone maker Huawei. Huawei was sanctioned by the US Administration, both as retaliation for intellectual property theft and as a protectionist measure for US network device makers. At the same time, there are positive reasons why this company is on the analysts’ radar.Michael Genovese (a 4-star analyst according to TipRanks) of MKM Partners noted the Huawei exposure, adding, “The company has determined that most of the products it ships to Huawei are not subject to the Entity List restrictions, with good demand being seen for its 100G/200G products. We see 28% sequential increase in sales to the company's next four largest customers after Huawei, and demand trends are strong across Telecom and DCI applications.” Genovese raised his price target on NPTN to $7, suggesting a 14% upside to the stock.He wasn’t the only analyst to take an upbeat message from NeoPhotonic’s quarterly report. Jun Zhang (a 4-star analyst), from Rosenblatt Securities, also rates the stock a buy, with a high $10 price target. Zhang wrote: “NeoPhotonics saw strong demand in the DCI and metro markets from Western customers... In addition, 400G related products ramped quickly, while 25G EML lasers are seeing a strong ramp and now account for 10% of revenue. We expect NeoPhotonics to continue to benefit from the initial deployment of 400G/600G networks.” Zhang’s price target implies an impressive 63% upside potential for NPTN.NeoPhotonics shares jumped 46% after the Q2 report, and now stand at $6.10. The average price target, $7.71, indicates a potential upside of 26%. The stock has a Strong Buy rating from the analyst consensus, with 6 buys and 1 hold given in the past three months. nLight, Inc. (LASR)Also an industrial and optoelectronic laser company, nLight’s business has also suffered from China exposure. But where NeoPhotonics reported a quarterly loss, nLight reported a gain of 5 cents per share. That still represented a 16% miss, but the quarterly revenues of $48.05 million were in line with expectations.While nLight’s stock has dropped sharply in the past year, the company remains profitable and analysts see the headwinds easing in the longer-term. DA Davidson’s Thomas Diffely (a 5-star analyst according to TipRanks) pointed out the pressures, including industry concerns over US-China trade issues, increased pricing pressure from China’s domestic competitors, and a slowing industrial laser market. On the positive side, he says, “[LASR’s] Aerospace and Defense segment remains a bright spot with its sixth consecutive quarter of double-digit growth.” That’s enough for him to maintain his buy rating on the stock, with a $20 price target and a 37% upside.Agreeing with Difflely on the bullish prospects for LASR are Needham’s James Ricchiuti (a 5-star analyst) and Stifel’s Patrick Ho (a 5-star analyst). They set price targets of $19 and $24, respectively.LASR shares are the highest priced of the stocks were looking at here, currently trading at $14.60. The stock has an average price target of $19.33 and a potential upside of 32%. The Moderate Buy analyst consensus rating comes from 4 buys and 3 holds given over the past three months. ViewRay, Inc. (VRAY)ViewRay is a pioneer in medical imagery, developing MRI technology to provide real-time imaging to improve the accuracy and delivery of radiation treatments, allowing greater benefits to the patient from lower radiation doses. And like many high-tech companies at the cutting edge of their fields, ViewRay has consistently reported quarterly losses. At the same time, high revenues offer a compelling bull case for VRAY.Losses aren’t necessarily cause for concern, as they are usually baked into the pricing of tech startups. ViewRay took a 32 cent per share hit in Q2, but on a positive note, revenue was up. The quarterly revenue of $30.17 million beat the estimate by 12.57% and was nearly double the year-ago quarter’s $16.44 million.That strong revenue beat carried the day, as far as Wall Street’s analysts were concerned. Buy pushing down the stock price – VRAY dropped from $9 to $3 after the quarterly release – the earnings report has opened up a buying opportunity for this stock. Jefferies analyst Anthony Petrone (a 4-star analyst) lists everything that went wrong for ViewRay in the quarter before coming to his conclusion: “We remain positive on the long-term prospects for MRIdian. Keep a Buy rating on ViewRay.” His price target, $7, underlines his optimism with an upside of 125%.Writing from Northland Securities, Suraj Kalia (a 4-star analyst) noted, “Unit orders beginning Q1-18 have been 4, 6, 6, 8, 7, and 3, respectively. Our FY19 unit order estimate goes to 24 units (from 31). FY20 unit orders @ 54 remains unchanged.” Kalia’s $5 price target suggests a 61% upside.The most optimistic take on VRAY comes from Andrew D’silva (a 3-star analyst) of B. Riley FBR. D’silva points out that, despite growing competition, ViewRay has more product installations during the quarter than expected: “The top-line beat was primarily due to VRAY installing 5 MRIdian Linacs versus our expectation for 4.” He gives the stock a $9 price target, suggesting an impressive 190% upside.Overall, VRAY has a Strong Buy from the analyst consensus, based on a unanimous 7 buy ratings. The stock is priced at $3.10, and the average price target of $7.86 gives it a 153% upside.Visit TipRanks’ Top Analysts page to find out which stocks are stirring up notice on the Street.
ViewRay (VRAY) delivered earnings and revenue surprises of -39.13% and 12.57%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
CLEVELAND , Aug. 8, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the second quarter ended June 30, 2019 . Second Quarter 2019 Summary: The Company is updating ...
ViewRay (VRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ViewRay will hold a conference call to discuss results on Thursday, August 8, 2019 at 4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525-7129 for international callers. The conference ID number is 1695303.
CLEVELAND, July 16, 2019 /PRNewswire/ -- ViewRay, Inc. (VRAY) announced the appointment of Dr. Gail Wilensky to its Board of Directors, effective today. Dr. Wilensky has an extensive track record in healthcare as a policy leader, reimbursement expert, and board member. Gail was also the first chair of the Medicare Payment Advisory Commission.
Company officials, who have had a small presence in Colorado for several years, said they are "very impressed" with the local workforce.
Presentations Highlight MRIdian Clinical Experience with Real-Time On-Table Adaptive Radiotherapy at a Growing Number of Institutions Worldwide CLEVELAND , July 10, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: ...
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
You don’t have to pay three-digit sums to find compelling investing opportunities. It’s time to look outside the box at some cheap stocks top analysts are cheering right now. The best way to find these stocks is to use a screener, that way you can open up your investing horizon to a much wider stock pool.Here we used TipRanks’ Stock Screener to find these 5 cheap stocks. Essentially, we looked for 1) stocks with a ‘Strong Buy’ analyst consensus; 2) serious upside potential (i.e. over 20%). And on top of this each one of these stocks comes in at under $10. Note that the consensus is based on ratings from the last three months, so the outlook is pretty up to date. Plus we include top analyst analysis to show just why analysts believe these stocks are so undervalued right now.Let’s take a closer look: Syndax Pharmaceuticals Inc (SNDX – Research Report) Syndax Pharmaceuticals, Inc is a clinical-stage biopharma developing therapies for the treatment of cancer.The company offers significant rewards- but only for investors prepared to shoulder a hefty dose of risk. Shares could surge if the company’s Phase 3 trial of entinostat in metastatic breast cancer is positive. Indeed, Citigroup’s Joel Beatty says that such a catalyst could take shares all the way from $8 to $23. That suggests massive upside potential of 187%. However, the analyst also warns that should the data disappoint, shares could plunge to just $2 (75% downside potential). Look for the data to come in fall 2019 or spring 2020, says Beatty. In the meantime the analyst keeps a buy rating on shares. Encouragingly, the stock also scores a Strong Buy consensus from the Street. “Entinostat has received Breakthrough Therapy Designation in HR+ HER2- breast cancer patients, and we continue to believe that a positive OS assessment in E2112 could occur this year with a launch in 2021” writes HC Wainwright analyst Edward White. This five-star analyst has a $16 price target on shares (100% upside potential). That's just below the $19 average analyst price target. See what other Top Analysts are saying about SNDX. Turtle Beach Corp (HEAR – Research Report) Turtle Beach Corp is one of the leading gaming headset and audio accessory brand. Disappointing 2Q revenue guidance has weighed on shares recently, but it’s not game over for HEAR just yet.All five analysts covering the stock rate HEAR a ‘Buy.’ That’s with an average analyst price target of $23- indicating 150% upside potential from current levels. The best-rated analyst covering the stock is Oppenheimer’s Andrew Uerkwitz.He maintained his buy rating and $24 price target post-results. In a report on May 9 the analyst explained “With healthy fundamentals in video game market and integration of PC gaming accessories business (ROCCAT) well on track, we remain confident in management's ability to stay competitive and return to revenue growth in 2020.”As for the earnings report, the analyst explains that 2Q revenue guidance is lighter than expected, mostly due to order timing volatility in between quarters. However HEAR did reiterate 2019 revenues of $240-248M. “Over a two year basis, we believe Turtle Beach is outgrowing the competition and keeping its leading market share” he concludes. See what other Top Analysts are saying about HEAR. Pareteum Corp (TEUM – Research Report) Pareteum is a rapidly growing global cloud software communications platform. The company offers everything from voicemail and messaging services to data analytics and service fulfilment. Shares have exploded by 150% year-to-date following first-rate Q1 earnings results, and according to the analyst community plenty of upside lies ahead. This ‘Strong Buy’ stock scores 5 recent buy ratings, alongside an $8 average analyst price target (86% upside potential).Pareteum just hosted its first analyst day on May 28 in NYC. “We view this event as another sign of the further and rapid maturation of the company” cheers five-star Northland Securities analyst Michael Latimore. He has an $8.50 price target on shares. According to Latimore, Pareteum has a unique opportunity to be the cloud-based business and operations support system for agile mobile service providers. “TEUM is a top 2019 stock pick…. TEUM remains inexpensive still at only about 4x FY20 revenue v. comps at 10x” writes the analyst. See what other Top Analysts are saying about TEUM. Plug Power Inc (PLUG – Research Report) Plug Power develops cutting-edge fuel cells and hydrogen technologies that are more efficient than conventional batteries. Like Paretuem, PLUG has experienced a remarkable rally, with shares doubling year-to-date.Shares continued to move higher on May 29 following the announcement of an exciting new deal. Plug Power will now deliver hydrogen fuel cell engines to StreeScooter’s electric delivery vehicles. This ties into StreetScooter’s deal to initially deliver 100 hydrogen fuel cell-powered trucks for on-road use to Deutsche Post DHL starting in 2020. According to Plug Power this will provide increased drive time without the need for long charge hours.“We continue to be bullish on PLUG’s technology leadership position in mobile fuel cell applications and are encouraged by commentary about its expanding opportunity set in material handling and over-the-road applications” writes top-rated Oppenheimer analyst Colin Rusch. Four analysts have published buy ratings on PLUG in the last three months. Their average price target of $3.56 translates into upside potential of 37%. See what other Top Analysts are saying about PLUG. ViewRay, Inc. (VRAY – Research Report) Medical device company ViewRay is on a roll right now. The company just reported strong earnings results, and shares are up 47% year-to-date. Sean Lavin of BTIG praised the company’s current investment strategy, noting strong sales and steady sales progress. Indeed, gross orders came in an impressive $12 million above consensus. “This is especially important as it shows VRAY is winning new customers despite the recent competitive entrance from Elekta. While sales and orders can be difficult to predict on a quarterly basis, we believe this is an early sign that the new CEO’s strategy is working” wrote Lavin. The analyst concluded “since orders are likely most important to investors, we view this as a stellar report.”A similarly bullish perspective comes from Cantor Fitzgerald’s Craig Bijou. The analyst left a recent meeting with management "more bullish on the opportunity ahead” for ViewRay. Despite the rally in shares, he still sees ‘significant upside’ potential thanks to increased revenue and margin expansion.Notably, Bijou argues that management's goal to reduce the time from purchase order to revenue recognition could drive "meaningful upside" to Street numbers in 2020. Overall, five analysts have published buy ratings on VRAY in the last three months with an average price target of $13.40 (50% upside potential). See what other Top Analysts are saying about VRAY. Find your own ‘Strong Buy’ stocksHere we covered top stock picks currently trading for under $10. You can discover more compelling 'Strong Buy' stocks with the Top Analyst Stocks tool. This highlights the most promising stocks based on the latest recommendations from the Street's best-performing analysts. Go to Top Analysts Stocks Tool now.
CLEVELAND, May 22, 2019 /PRNewswire/ -- ViewRay, Inc. (VRAY) announced today that the clinical team at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis has treated its 1,000th patient using MRIdian MR-guided radiation therapy. Siteman Cancer Center helped pioneer MR-guided radiation therapy, becoming the first center to treat patients with MRIdian in January 2014.
CLEVELAND , May 16, 2019 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will participate in the Jefferies 2019 Global Healthcare Conference in New York, New York . Scott ...
"October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87\. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]